Frikha N, Ellachtar M, Mebazaa M S, Ben Ammar M S
Department of Anesthesia and Critical Care, Mongi Slim Hospital, Sidi Daoud, Tunisie.
Middle East J Anaesthesiol. 2007 Feb;19(1):87-96.
Combined spinal-epidural (CSE) analgesia is becoming increasingly used to provide pain relief during labor. It combines both the rapid onset of the spinal analgesia and the flexibility of the epidural catheter. Intrathecal sufentanil provides rapid-onset and profound analgesia during the first stage of labor. The dose required to produce this effect can be associated with maternal respiratory depression, hypotension, nausea, or pruritus. The major concern of the anesthesiologist is to limit these side effects sources of discomfort to a parturient, by choosing the optimal dose of sufentanil or searching for an alternative. The purpose of this study is to compare tramadol and sufentanil used in CSE analgesia in terms of duration of analgesia and frequency of adverse maternal or fetal effects.
Forty parturients requesting labor analgesia were included in this prospective study. In a combined spinal- epidural technique, at 3 to 4 cm cervical dilation, patients were randomly assigned to receive either one of the following intrathecal solutions: 2.5 mg sufentanil (n = 20) and 2.5 mg bupivacaine, or 25 mg tramadol (n = 20) and 2.5 mg bupivacaine. Visual analog scores for pain, blood pressure, heart rate, sensory levels, incidence of nausea and pruritus, motor blockade, and maternal satisfaction, were recorded.
Patients receiving 25 mg intrathecal tramadol with 2.5 mg bupivacaine had significantly longer-lasting analgesia (114 +/- 7 min). than those receiving 2.5 mg intrathecal sufentanil and 2.5 mg bupivacaine (54 +/- 11 min). No adverse maternal or fetal effects were noted in the group sufentanil. Five parturients of the tramadol group, presented vomiting 10 min after induction. There was no difference in the time from analgesia to delivery, incidence of operative or assisted delivery or cervical dilation. During labor, maternal satisfaction was good.
2.5 micrograms of intrathecal sufentanil combined with 2.5 mg bupivacaine provides rapid-onset and profound analgesia during the first stage of labor without adverse maternal or fetal effects. 25 mg intrathecal tramadol with 2.5 mg bupivacaine had longer-lasting analgesia. The major side effect was vomiting.
腰麻-硬膜外联合(CSE)镇痛在分娩过程中用于缓解疼痛的应用越来越广泛。它结合了腰麻镇痛起效迅速和硬膜外导管的灵活性。鞘内注射舒芬太尼在分娩第一阶段可提供起效迅速且强效的镇痛。产生这种效果所需的剂量可能与产妇呼吸抑制、低血压、恶心或瘙痒有关。麻醉医生主要关注的是通过选择舒芬太尼的最佳剂量或寻找替代药物,将这些副作用(给产妇带来不适的根源)降至最低。本研究的目的是比较曲马多和舒芬太尼用于CSE镇痛时的镇痛持续时间以及产妇或胎儿不良影响的发生率。
本前瞻性研究纳入了40名要求分娩镇痛的产妇。采用腰麻-硬膜外联合技术,在宫颈扩张3至4厘米时,患者被随机分配接受以下鞘内溶液之一:2.5毫克舒芬太尼(n = 20)加2.5毫克布比卡因,或25毫克曲马多(n = 20)加2.5毫克布比卡因。记录疼痛视觉模拟评分、血压、心率、感觉平面、恶心和瘙痒发生率、运动阻滞情况以及产妇满意度。
接受25毫克鞘内曲马多加2.5毫克布比卡因的患者镇痛持续时间显著更长(114±7分钟),比接受2.5毫克鞘内舒芬太尼加2.5毫克布比卡因的患者(54±11分钟)长。舒芬太尼组未观察到产妇或胎儿的不良影响。曲马多组有5名产妇在诱导后10分钟出现呕吐。镇痛至分娩的时间、手术或辅助分娩的发生率或宫颈扩张情况无差异。分娩期间,产妇满意度良好。
鞘内注射2.5微克舒芬太尼联合2.5毫克布比卡因在分娩第一阶段可提供起效迅速且强效的镇痛,且无产妇或胎儿不良影响。鞘内注射25毫克曲马多联合2.5毫克布比卡因镇痛持续时间更长。主要副作用是呕吐。